Brokerages Set Qiagen (NYSE:QGEN) PT at $51.10

Shares of Qiagen (NYSE:QGEN) have been given a consensus rating of “Moderate Buy” by the nine research firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $51.10.

QGEN has been the topic of a number of recent analyst reports. Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research note on Thursday, June 27th. JPMorgan Chase & Co. lifted their price objective on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 18th. Finally, Robert W. Baird lifted their price objective on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd.

Qiagen Trading Down 0.6 %

Qiagen stock opened at $45.57 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. The business’s 50-day simple moving average is $44.25 and its 200-day simple moving average is $43.36. The firm has a market capitalization of $10.40 billion, a PE ratio of 30.58, a PEG ratio of 3.17 and a beta of 0.39. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.44.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. Equities research analysts forecast that Qiagen will post 2.15 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Toronto Dominion Bank bought a new stake in shares of Qiagen during the 2nd quarter valued at $27,000. Riverview Trust Co bought a new position in Qiagen during the 1st quarter worth about $28,000. Park Place Capital Corp bought a new position in Qiagen during the 1st quarter worth about $36,000. Quarry LP acquired a new position in shares of Qiagen during the 4th quarter worth about $38,000. Finally, CWM LLC boosted its stake in shares of Qiagen by 19.1% during the 1st quarter. CWM LLC now owns 2,236 shares of the company’s stock worth $96,000 after buying an additional 358 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.